These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Lipoprotein(a): an important cardiovascular risk factor and a clinical conundrum. Koschinsky ML; Boffa MB Endocrinol Metab Clin North Am; 2014 Dec; 43(4):949-62. PubMed ID: 25432390 [TBL] [Abstract][Full Text] [Related]
5. Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis. Burgess S; Ference BA; Staley JR; Freitag DF; Mason AM; Nielsen SF; Willeit P; Young R; Surendran P; Karthikeyan S; Bolton TR; Peters JE; Kamstrup PR; Tybjærg-Hansen A; Benn M; Langsted A; Schnohr P; Vedel-Krogh S; Kobylecki CJ; Ford I; Packard C; Trompet S; Jukema JW; Sattar N; Di Angelantonio E; Saleheen D; Howson JMM; Nordestgaard BG; Butterworth AS; Danesh J; JAMA Cardiol; 2018 Jul; 3(7):619-627. PubMed ID: 29926099 [TBL] [Abstract][Full Text] [Related]
6. Lipoprotein (a): a prothrombotic risk factor for coronary artery disease. Seed M; Doherty E; Stubbs P J Cardiovasc Risk; 1995 Jun; 2(3):206-15. PubMed ID: 7584795 [TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease. Sandholzer C; Boerwinkle E; Saha N; Tong MC; Utermann G J Clin Invest; 1992 Mar; 89(3):1040-6. PubMed ID: 1541665 [TBL] [Abstract][Full Text] [Related]
8. Estimation of the Required Lipoprotein(a)-Lowering Therapeutic Effect Size for Reduction in Coronary Heart Disease Outcomes: A Mendelian Randomization Analysis. Lamina C; Kronenberg F; JAMA Cardiol; 2019 Jun; 4(6):575-579. PubMed ID: 31017618 [TBL] [Abstract][Full Text] [Related]
9. Apheresis in coronary heart disease with elevated Lp (a): a review of Lp (a) as a risk factor and its management. Keller C Ther Apher Dial; 2007 Feb; 11(1):2-8. PubMed ID: 17309568 [TBL] [Abstract][Full Text] [Related]
10. Screening and therapeutic management of lipoprotein(a) excess: review of the epidemiological evidence, guidelines and recommendations. Lippi G; Franchini M; Targher G Clin Chim Acta; 2011 May; 412(11-12):797-801. PubMed ID: 21256836 [TBL] [Abstract][Full Text] [Related]
11. [Coronary heart disease and lipoprotein (a): relationship with other lipid cardiovascular risk factors]. Nogués X; Sentí M; Pedro-Botet J; Molina L; Serrat R; Pons S; Rubiés-Prat J Med Clin (Barc); 1992 Feb; 98(5):171-4. PubMed ID: 1532436 [TBL] [Abstract][Full Text] [Related]
12. Lipoprotein(a) as a therapeutic target in cardiovascular disease. Koschinsky M; Boffa M Expert Opin Ther Targets; 2014 Jul; 18(7):747-57. PubMed ID: 24848373 [TBL] [Abstract][Full Text] [Related]
13. [Apolipoprotein(a) phenotypes as markers of genetic susceptibility for cardiovascular risk in occupational medicine]. Mennoia NV; Gazzaruso C; Geroldi D; Candura SM G Ital Med Lav Ergon; 1999; 21(3):206-17. PubMed ID: 10771732 [TBL] [Abstract][Full Text] [Related]
14. Impact of elevated serum lipoprotein (a) concentrations on the risk of coronary heart disease in patients with type 2 diabetes mellitus. Murase T; Okubo M; Amemiya-Kudo M; Ebara T; Mori Y Metabolism; 2008 Jun; 57(6):791-5. PubMed ID: 18502261 [TBL] [Abstract][Full Text] [Related]
15. [Elevated levels of lipoprotein(a) are present in subjects with early ischemic cardiopathy and with a familial history of ischemic cardiopathy]. Saitta A; Castaldo M; Sardo A; Cinquegrani M; Bonaiuto M; Zema M; Gravina M; Mangano C Minerva Med; 1999; 90(5-6):151-8. PubMed ID: 10780189 [TBL] [Abstract][Full Text] [Related]
16. Genetics and metabolism of lipoprotein(a) and their clinical implications (Part 1). Dieplinger H; Kronenberg F Wien Klin Wochenschr; 1999 Jan; 111(1):5-20. PubMed ID: 10067265 [TBL] [Abstract][Full Text] [Related]